Vertex Pharmaceuticals (VRTX) Receivables (2009 - 2026)

Vertex Pharmaceuticals' Receivables history runs 18 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• On a quarterly basis, Receivables rose 10.58% year-over-year to $2.0 billion in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 10.58% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 27.55% from the prior year.
• Receivables slipped to $2.0 billion in Q1 2026 per VRTX's latest filing, from $2.1 billion in the prior quarter.
• Across five years, Receivables topped out at $2.1 billion in Q4 2025 and bottomed at $1.3 billion in Q1 2022.
• The 5-year median for Receivables is $1.6 billion (2024), against an average of $1.7 billion.
• Across the five-year window, Receivables soared 43.45% in 2022 and grew 0.66% in 2025, its largest moves.
• Year by year, Receivables stood at $1.4 billion in 2022, then gained by 8.4% to $1.6 billion in 2023, then rose by 2.94% to $1.6 billion in 2024, then increased by 27.55% to $2.1 billion in 2025, then fell by 2.76% to $2.0 billion in 2026.
• Per Business Quant, the three latest VRTX Receivables figures stand at $2.0 billion (Q1 2026), $2.1 billion (Q4 2025), and $1.9 billion (Q3 2025).